Johnson & Johnson, J&j | featured news

J&J to buy Synthes for $21.5 billion: report

J&J to buy Synthes for $21.5 billion: report

Johnson & Johnson is to buy Swiss medical devices maker Synthes Inc in a deal worth $21.3 billion, its largest ever buy, boosting its orthopedics franchise and reshaping the medical technology industry.

 

Johnson & Johnson to Reorganize Troubled Tylenol Unit

Johnson & Johnson is revamping the troubled unit that makes Tylenol and giving it new leadership in an effort to fix quality problems that have prompted multiple recalls, according to people familiar with the matter.

 

9 million bottles of Tylenol recalled

Johnson & Johnson said on Wednesday that it was recalling 9 million more bottles of its Tylenol painkiller because they did not adequately warn customers about the presence of trace amounts of alcohol used in the product flavorings.

 

J&J recall saga continues with Children's Benadryl

Johnson & Johnson's McNeil unit has begun a voluntary recall of Children's Benadryl allergy tablets, in cherry and grape flavors, citing insufficiencies in the development of the manufacturing process.

 

J&J Heart Drug Provided Little Symptom Benefit

J&J Heart Drug Provided Little Symptom Benefit

Results of a long-awaited clinical trial show J&J's drug nesiritide provides limited relief from breathing problems for patients with acute heart failure.

 

J&J CEO faces U.S. lawmakers over string of recalls

Johnson & Johnson's massive recall of faulty medicines, including a quiet buyback of its Motrin painkiller, has angered U.S. lawmakers who will question the company's chief executive and a senior health regulator on Thursday.

 

Did drugmaker hide birth control patch risks?

According to private internal documents obtained by NBC News, pharmaceutical giant Johnson & Johnson may have known about deadly risks of its birth control patch Ortho Evra years ago, but kept the product on the market anyway.

 

J&J to cut 7,000 to 8,000 jobs

Johnson & Johnson will eliminate about 6 percent to 7 percent of its global workforce, or some 7,000 to 8,000 positions, as the diversified healthcare company restructures and seeks cost savings, the company said on Tuesday.

 

Subscribe to this RSS topic: Syndicate content